Esperion Therapeutics, Inc.

Reported to SECin USCIK 0001434868Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 30. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 30
Form 4 lines at Esperion Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Hoffman Robert E.—Returned to the issuer—7,040 sharesJul 13, 2026Hoffman Robert E.—Returned · Jul 13Returned to the issuer7,040Jul 13, 2026
Hoffman Robert E.—Returned to the issuer—40,000 sharesJul 13, 2026Hoffman Robert E.—Returned · Jul 13Returned to the issuer40,000Jul 13, 2026
Hoffman Robert E.—Returned to the issuer—85,153 sharesJul 13, 2026Hoffman Robert E.—Returned · Jul 13Returned to the issuer85,153Jul 13, 2026
CARROLL J MARTIN—Returned to the issuer—44,000 sharesJul 13, 2026CARROLL J MARTIN—Returned · Jul 13Returned to the issuer44,000Jul 13, 2026
CARROLL J MARTIN—Returned to the issuer—32,500 sharesJul 13, 2026CARROLL J MARTIN—Returned · Jul 13Returned to the issuer32,500Jul 13, 2026